Samil to release FDA-approved conjunctivitis treatment

Partnership with French ophthalmology company Nicox S.A. on Zerviate

Shooting for a launch in 2020, Samil Pharm to manufacture and commercialize in Korea

On Dec.

 

6, Samil Pharm announced it signed a manufacturing and commercialization license with a France-based ophthalmic R&D company, Nicox S.A.

 

for the exclusiv rights of allergic conjunctivitis treatment Zerviate (cetirizine) in Korea.

 

By closing the deal, Samil Pharm would receive the exclusive rights to manufacture and commercialize the ophthalmic solution and start preparing for the release in 2022.

 

The U.S.

 

health regulator granted an approval on Zerviate for preventing ocular itching associated with allergic conjunctivitis in 2017.

 

The treatment is preparing for a launch in early next year.

 

It is the first and only ophthalmic solution to be made with cetirizine.

 

A Phase 3 clinical study in the U.S.

 

demonstrated significantly less ocular itching within a short period of time.

 

The trial also confirmed safety of the solution so that it could be prescribed to a child aged at two and up.

 

Allergic conjunctivitis is an allergic reaction causing conjunctivitis, an inflammation of the thin layer on the surface of the eye.

 

The signs and symptoms may include eye redness, excessive watering, itchy burning eyes, discharge and blurred vision.

 

With its headquarters in France, Nicox S.A.

 

is an international ophthalmology company focused on development and commercialization of ophthalmic pipeline.

 

Other than Zerviate, Nicox S.A.’s ophthalmic pipeline cover glaucoma and other ocular diseases, developed with the company’s novel nitric oxide-donating R&D platform.

 

Based on the technology, a glaucoma treatment Vyzulta (latanoprostene bunod ophthalmic solution) has been commercialized in the U.S.

 

since December 2017.